JP2002544238A5 - - Google Patents

Download PDF

Info

Publication number
JP2002544238A5
JP2002544238A5 JP2000617920A JP2000617920A JP2002544238A5 JP 2002544238 A5 JP2002544238 A5 JP 2002544238A5 JP 2000617920 A JP2000617920 A JP 2000617920A JP 2000617920 A JP2000617920 A JP 2000617920A JP 2002544238 A5 JP2002544238 A5 JP 2002544238A5
Authority
JP
Japan
Prior art keywords
tumor
medicine
patient
treating
erbb2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000617920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544238A (ja
JP5623681B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/012552 external-priority patent/WO2000069460A1/en
Publication of JP2002544238A publication Critical patent/JP2002544238A/ja
Publication of JP2002544238A5 publication Critical patent/JP2002544238A5/ja
Application granted granted Critical
Publication of JP5623681B2 publication Critical patent/JP5623681B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000617920A 1999-05-14 2000-05-09 抗−ErbB2抗体による治療 Expired - Lifetime JP5623681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13408599P 1999-05-14 1999-05-14
US60/134,085 1999-05-14
PCT/US2000/012552 WO2000069460A1 (en) 1999-05-14 2000-05-09 TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011156126A Division JP2011246480A (ja) 1999-05-14 2011-07-14 抗−ErbB2抗体による治療

Publications (3)

Publication Number Publication Date
JP2002544238A JP2002544238A (ja) 2002-12-24
JP2002544238A5 true JP2002544238A5 (cg-RX-API-DMAC7.html) 2007-06-21
JP5623681B2 JP5623681B2 (ja) 2014-11-12

Family

ID=22461712

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000617920A Expired - Lifetime JP5623681B2 (ja) 1999-05-14 2000-05-09 抗−ErbB2抗体による治療
JP2011156126A Withdrawn JP2011246480A (ja) 1999-05-14 2011-07-14 抗−ErbB2抗体による治療
JP2014151231A Pending JP2015007056A (ja) 1999-05-14 2014-07-24 抗−ErbB2抗体による治療
JP2016000187A Pending JP2016128428A (ja) 1999-05-14 2016-01-04 抗−ErbB2抗体による治療
JP2017074178A Withdrawn JP2017160210A (ja) 1999-05-14 2017-04-04 抗−ErbB2抗体による治療
JP2018207867A Pending JP2019055961A (ja) 1999-05-14 2018-11-05 抗−ErbB2抗体による治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2011156126A Withdrawn JP2011246480A (ja) 1999-05-14 2011-07-14 抗−ErbB2抗体による治療
JP2014151231A Pending JP2015007056A (ja) 1999-05-14 2014-07-24 抗−ErbB2抗体による治療
JP2016000187A Pending JP2016128428A (ja) 1999-05-14 2016-01-04 抗−ErbB2抗体による治療
JP2017074178A Withdrawn JP2017160210A (ja) 1999-05-14 2017-04-04 抗−ErbB2抗体による治療
JP2018207867A Pending JP2019055961A (ja) 1999-05-14 2018-11-05 抗−ErbB2抗体による治療

Country Status (13)

Country Link
US (4) US20030170235A1 (cg-RX-API-DMAC7.html)
EP (1) EP1187632B1 (cg-RX-API-DMAC7.html)
JP (6) JP5623681B2 (cg-RX-API-DMAC7.html)
AT (1) ATE415979T1 (cg-RX-API-DMAC7.html)
AU (1) AU782325B2 (cg-RX-API-DMAC7.html)
CA (1) CA2374085C (cg-RX-API-DMAC7.html)
CY (1) CY1108765T1 (cg-RX-API-DMAC7.html)
DE (1) DE60040981D1 (cg-RX-API-DMAC7.html)
DK (1) DK1187632T3 (cg-RX-API-DMAC7.html)
ES (1) ES2320311T3 (cg-RX-API-DMAC7.html)
PT (1) PT1187632E (cg-RX-API-DMAC7.html)
SI (1) SI1187632T1 (cg-RX-API-DMAC7.html)
WO (1) WO2000069460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AT413487B (de) * 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
CA2606081C (en) * 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
EP1912680B1 (en) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
MX2011003381A (es) * 2008-09-30 2011-04-21 Abbott Lab Metodo mejorado para despliegue de arn.
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Light標的分子およびその使用
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
EP2373338B1 (en) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック, インコーポレイテッド Her2陽性転移性乳癌の治療方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック, インコーポレイテッド 進行したher2発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック, インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Similar Documents

Publication Publication Date Title
RU2430739C9 (ru) Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты)
MXPA02010059A (es) Metodo para administrar un anticuerpo.
JP2020536109A5 (cg-RX-API-DMAC7.html)
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
JP2020510039A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
JP2002535285A5 (cg-RX-API-DMAC7.html)
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
JP2004512262A5 (cg-RX-API-DMAC7.html)
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
EP1410804A4 (en) CANCER VACCINE WITH CANCER ANTIGENS BASED ON TUMOR SUPPRESSOR GEN WT1 PRODUCT AND CATIONIC LIPOSOME
JP2006506441A5 (cg-RX-API-DMAC7.html)
HUP0401605A2 (hu) Szembetegségek kezelésére szolgáló integrin gátlók
WO2004002445A3 (en) Novel floating dosage form
JP2013533269A (ja) 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
IL182352A (en) Use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
JP2002528502A5 (cg-RX-API-DMAC7.html)
EP1758998A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES
CN116712539A (zh) 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途